Werner Lanthaler
CEO @ Evotec
Hamburg, Germany
Werner Lanthaler is a seed investor at Evotec in Hamburg focused on Health Care and Biotechnology. Dr Werner Lanthaler (born in 1968, Austrian citizen) was appointed Chief Executive Officer of Evotec on 06 March 2009. His current term will expire on 05 March 2021. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccineplayer. Dr Lanthaler played a pivotal role in many of the company's major corporate milestones including the product approval of Intercell's Japanese Encephalitis Vaccine, the company's acquisitions and strategic pharma partnerships, as well as the company's Initial Public Offering in 2005. Previously, from 1998 to 2000 Dr Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company. He holds a doctorate in economics from Vienna University, earned his Master’s degree from Harvard University and holds a degree in Psychology. Dr Werner Lanthaler serves in the Boards of Directors of AC Immune SA (since July 2018) and argenx SE (since April 2014), where he also serves as Chairman of the Audit Committee. He is also a member of the Supervisory Board of Topas Therapeutics GmbH (since October 2015).
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Werner Lanthaler invests in
Stages Werner Lanthaler invests in
Countries Werner Lanthaler invests in
Investment Focus
Industry
- Health Care 2 (40%)
- Biotechnology 2 (40%)
- Pharmaceutical 2 (40%)
- Medical 1 (20%)
- Health Diagnostics 1 (20%)
Stage
- Seed 1 (20%)
- Series A 1 (20%)
- Series B 1 (20%)
- Series C 1 (20%)
Country
- Austria 1 (20%)
- United Kingdom 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
aTension.life
|
aTension.life is a company focused on advancing the diagnosis and treatment of hypertension through precision medicine. It employs cutting-edge mass spectrometry technology to identify the underlying causes of uncontrolled hypertension using a single blood sample. aTension.life aims to provide personalized diagnostic solutions that enhance patientcare and support laboratories with accurate and reliable tools. The company's mission is to improve the quality of life for hypertensive patients by making advanced diagnostics widely accessible and enabling more effective, individualized therapies. | $3M / Seed / Apr 10, 2025 | |
Exscientia
|
Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize thepharmaceutical industry. | $40M / Series C / Mar 04, 2021 | |
|
Exscientia
|
Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize thepharmaceutical industry. | $60M / Series C / May 26, 2020 | |
|
Exscientia
|
Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize thepharmaceutical industry. | $26M / Series B / Jan 07, 2019 | |
|
Exscientia
|
Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize thepharmaceutical industry. | $16.5M / Series A / Sep 28, 2017 |
Co-Investors
About Evotec
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances,development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased, and comprehensive infrastructure.Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Sanofi in the field of diabetes and cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases, and with Celgene in the field of neurodegenerative diseases.
Evotec Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Werner Lanthaler
CEO
|
|||
Aurelie Dalbiez
Chief People Officer
|
|||
Cord Dohrmann
CSO & Managment board member
|
|||
Craig Johnstone
Chief Operating Officer
|
|||
Dimitar Hristozov
Group Leader & Research Informatics
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Werner Lanthaler invest in?
Werner Lanthaler invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Werner Lanthaler last invest?
The most recent investment recorded for Werner Lanthaler closed in Apr 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
